{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:53:05Z","timestamp":1792641185472,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T00:00:00Z","timestamp":1399680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00256-014-1891-9","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T06:37:53Z","timestamp":1399617473000},"page":"1353-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat"],"prefix":"10.1007","volume":"43","author":[{"given":"Ravi S.","family":"Kamath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Watman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dragosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa Avila","family":"Arreguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Aguzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Puga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Norfleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,10]]},"reference":[{"issue":"6","key":"1891_CR1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2106\/00004623-198668060-00002","volume":"68","author":"DI Rosenthal","year":"1986","unstructured":"Rosenthal DI, Scott JA, Barranger J, Mankin HJ, Saini S, Brady TJ, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am. 1986;68(6):802\u20138.","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"1891_CR2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S Vom Dahl","year":"2006","unstructured":"Vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin. 2006;22(6):1045\u201364.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1891_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","volume":"104","author":"O Goker-Alpan","year":"2011","unstructured":"Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011;104(4):438\u201347.","journal-title":"Mol Genet Metab"},{"key":"1891_CR4","volume-title":"The metabolic and molecular bases of inherited disease","author":"E Beutler","year":"2001","unstructured":"Beutler E. Gaucher disease. In: Scriver CRBA, Sly W, Valle D, Childs R, Kinzler K, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001.","edition":"8"},{"issue":"5","key":"1891_CR5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","volume":"64","author":"DW Stowens","year":"1985","unstructured":"Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore). 1985;64(5):310\u201322.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"1891_CR6","first-page":"106","volume":"24","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24 Suppl 2:106\u201321. discussion 187\u2013108.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1891_CR7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1148\/radiology.182.2.1732964","volume":"182","author":"LA Johnson","year":"1992","unstructured":"Johnson LA, Hoppel BE, Gerard EL, Miller SP, Doppelt SH, Zirzow GC, et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology. 1992;182(2):451\u20135.","journal-title":"Radiology"},{"issue":"1","key":"1891_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46(1):66\u201372.","journal-title":"Blood Cells Mol Dis"},{"issue":"Suppl 1","key":"1891_CR9","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1259\/bjr.75.suppl_1.750013","volume":"75","author":"M Maas","year":"2002","unstructured":"Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol. 2002;75 Suppl 1:A13\u201324.","journal-title":"Br J Radiol"},{"issue":"9645","key":"1891_CR10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet"},{"key":"1891_CR11","unstructured":"Zavesca (Miglustat); full prescribing information. Actelion Pharmaceuticals 2013, http:\/\/www.zavesca.com\/pdf\/ZAVESCA-Full-Prescribing-Information.pdf ."},{"issue":"6","key":"1891_CR12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513\u201326.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1891_CR13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73(5):430\u201340.","journal-title":"Clin Genet"},{"issue":"1","key":"1891_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22(1):119\u201326.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1891_CR15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","volume":"29","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29(8):1645\u201354.","journal-title":"Clin Ther"},{"issue":"6","key":"1891_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893\u20139.","journal-title":"Blood"},{"issue":"20","key":"1891_CR17","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2\u00a0year results of a phase 2 study. Blood. 2010;116(20):4095\u20138.","journal-title":"Blood"},{"key":"1891_CR18","doi-asserted-by":"crossref","unstructured":"Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014; in press. doi: 10.1016\/j.bcmd.2014.04.002.","DOI":"10.1016\/j.bcmd.2014.04.002"},{"issue":"4 Pt 1","key":"1891_CR19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","volume":"96","author":"DI Rosenthal","year":"1995","unstructured":"Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995;96(4 Pt 1):629\u201337.","journal-title":"Pediatrics"},{"issue":"1","key":"1891_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","volume":"11","author":"S Baim","year":"2008","unstructured":"Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11(1):75\u201391.","journal-title":"J Clin Densitom"},{"issue":"1","key":"1891_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33\u20139.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1891_CR22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001;30(9):496\u2013503.","journal-title":"Skeletal Radiol"},{"issue":"10","key":"1891_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","volume":"29","author":"MR Terk","year":"2000","unstructured":"Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol. 2000;29(10):563\u201371.","journal-title":"Skeletal Radiol"},{"issue":"Suppl 1","key":"1891_CR24","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","volume":"75","author":"LW Poll","year":"2002","unstructured":"Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol. 2002;75 Suppl 1:A25\u201336.","journal-title":"Br J Radiol"},{"issue":"45","key":"1891_CR25","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A. 2010;107(45):19473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1891_CR26","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2011-0162","volume":"96","author":"L Dussen van","year":"2011","unstructured":"van Dussen L, Lips P, Everts VE, Bravenboer N, Jansen ID, Groener JE, et al. Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab. 2011;96(7):2194\u2013205.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"1891_CR27","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, Galipeau J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009;114(15):3181\u201390.","journal-title":"Blood"},{"issue":"5","key":"1891_CR28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","volume":"51","author":"MJ Peterschmitt","year":"2011","unstructured":"Peterschmitt MJ, Burke A, Blankstein L, Smith SE, Puga AC, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695\u2013705.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1891_CR29","first-page":"1169","volume":"11","author":"TM Cox","year":"2010","unstructured":"Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs. 2010;11(10):1169\u201381.","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"1891_CR30","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.ymgme.2011.11.091","volume":"105","author":"A Khan","year":"2012","unstructured":"Khan A, Hangartner T, Weinreb N, Taylor J, Mistry P. Risk factors for developing avascular necrosis or fractures in patients with type 1 Gaucher disease: analysis from the Gaucher Registry. Mol Genet Metab. 2012;105(2):S39\u201340.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1891_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71(3):205\u201311.","journal-title":"Clin Genet"},{"issue":"12","key":"1891_CR32","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2106\/00004623-200412000-00002","volume":"86-A","author":"EY Cheng","year":"2004","unstructured":"Cheng EY, Thongtrangan I, Laorr A, Saleh KJ. Spontaneous resolution of osteonecrosis of the femoral head. J Bone Joint Surg Am. 2004;86-A(12):2594\u20139.","journal-title":"J Bone Joint Surg Am"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00256-014-1891-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-014-1891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-014-1891-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T09:54:19Z","timestamp":1648979659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00256-014-1891-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1891"],"URL":"https:\/\/doi.org\/10.1007\/s00256-014-1891-9","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,10]]}}}